SCHOTT at CPhI Worldwide 2011

Date: 26 October 2011
Quality solutions for the pharmaceutical industryFrankfurt/Mainz, October 25, 2011 – SCHOTT Pharmaceutical Systems is showcasing its complete portfolio of products and solutions for the field of primary packaging for the pharmaceutical industry at Innopack in Frankfurt (Stand 40A24), which is taking place as part of CPhI trade fair from October 25 to 27, 2011.

Tobias Nemeth, Business Development Manager at SCHOTT, will be presenting at the Innopack Speakers Corner on Wednesday, October 26 at 3:30 pm. The topic of his presentation will be “Critical to quality aspects of glass syringes for use with auto-injector devices”.

Recent market recalls for injectable drug products due to visible flaky particles have put the topic of glass delamination into the focus of the industry. Based on more than 125 years of experience and strong analytical and material competence, SCHOTT offers different high-quality alternatives to conventional primary pharmaceutical glass packaging, but also provides analytical lab services for assessing the risk and root causes for glass delamination.

Resistant to delamination

In order to avoid the risk of glass particles, pharmaceutical companies can switch to SCHOTT TopPac® products which are made of COC high-tech polymer. It is also possible to benefit from the advantages of glass and at the same time being protected against glass particles. SCHOTT Type I plus® vials feature a coating layer that protects the formulation and the glass surface at the same time. Data generated in a six month accelerated ageing study confirms the resistance of SCHOTT Type I plus to delamination.

Tailor-made analytical lab services

A unique combination of specialized analytics and the company’s expertise in materials, products and processes enables SCHOTT pharma services to support pharmaceutical companies with test methods to assess the root cause and risk of delamination for different drug formulations and containers. With a self-developed delamination screening test, the likelihood for delamination occurring during the shelf life of a product can be assessed. The formation of particles on the container surface is often observed only after an extended time of storage. SCHOTT pharma services offers an accelerated compatibility test that reduces the testing period from months or years down to a few days. In cases where particles have already occurred, an in-depth particle analysis can help drawing conclusions on the particle development and forming process as well as creating strategies to avoid them.

About SCHOTT Pharmaceutical Systems

SCHOTT Pharmaceutical Systems is one of the world’s leading suppliers of glass tubing and primary packaging for the pharmaceutical industry. We provide our customers quality solutions while meeting their highest demands with our material expertise, specialized analytical lab services, and a broad product portfolio; including, syringes, cartridges, vials, ampoules, and special articles made of glass and COC polymer. With four glass tubing production sites and fifteen sites for pharmaceutical packaging spread over four continents, we offer safe supply and local service. Our state-of-the-art production facilities and our products comply with the highest international quality standards for pharmaceutical needs.


SCHOTT is an international technology group with more than 125 years of experience in the areas of specialty glasses and materials and advanced technologies. SCHOTT ranks number one in the world with many of its products. Its core markets are the household appliance, solar power, pharmaceuticals, electronics, optics, transportation and architecture industries. The company is strongly committed to contributing to its customers’ success and making SCHOTT an important part of people’s lives with high-quality products and intelligent solutions. SCHOTT is committed to managing its business in a sustainable manner and supporting its employees, society and the environment. The SCHOTT Group maintains close proximity to its customers with manufacturing and sales units in all major markets. Its workforce of around 17,500 employees generated worldwide sales of approximately 2.9 billion euros for the 2009/2010 fiscal year. SCHOTT AG, with its headquarters in Mainz (Germany) is owned by the Carl Zeiss Foundation.

600450 SCHOTT at CPhI Worldwide 2011
Date: 26 October 2011

See more news about:

See more from these topics:

Others also read

The 14th Otto Schott Research Award recognizes three researchers for their diverse findings on the strength of glass.
The 14th Otto Schott Research Award honors three researchers from three continents for their groundbreaking findings on the strength of glass
Since early researchers first became aware of their potentially deadly effects, the only confirmed form of protection available to those who were required to work with X-rays, gamma rays and similar emissions, was to conceal themselves behind lead sheeting or concrete walls.
SCHOTT PYRANOVA® integrity and insulation fire-resistant glass is being stocked for the first time at SCHOTT UK in Stafford.
SCHOTT’s glass wafers and substrates are transforming radio frequency components and micro-electromechanical systems. Advanced materials from SCHOTT, the international technology group and specialty glass experts, are shaking up the electronics industry.
New multimedia platform highlights innovations made possible with glass - SCHOTT, the international technology group, has launched an online platform that showcases the innovative potential of glass.

Add new comment